atoltivimab, maftivimab, and odesivimab-ebgn drug combination

Also Known As:

Inmazeb; R3470-3471-3479; REGN EB3; REGN-3470-3471-3479; REGN-EB3; REGN3470-3471-3479; REGNEB3; atoltivimab, maftivimab, and odesivimab drug combination; atoltivimab, maftivimab, odesivimab

Networked: 8 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ahuka-Mundeke, Steve: 2 articles (02/2024 - 11/2023)
2.	Sivapalasingam, Sumathi: 2 articles (10/2022 - 01/2018)
3.	Bastard, Mathieu: 1 article (02/2024)
4.	Bateyi Mustafa, Stephane Hans: 1 article (02/2024)
5.	Coulborn, Rebecca M: 1 article (02/2024)
6.	Gignoux, Etienne: 1 article (02/2024)
7.	Guai, Bérengère: 1 article (02/2024)
8.	Luquero, Francisco: 1 article (02/2024)
9.	Mukamba Musenga, Elisabeth: 1 article (02/2024)
10.	Peyraud, Nicolas: 1 article (02/2024)

Related Diseases

1.	Infections 01/01/2021 - "This article summarizes the milestones in the development of REGN-EB3 leading to this first approval for the treatment of infection caused by Zaire ebolavirus (Ebola virus) in adult and paediatric patients." 12/01/2021 - "Now two antibody drugs termed Inmazeb and Ebanga have been approved for treating EBOV infection. " 09/08/2022 - "Filovirus-specific monoclonal antibodies (mAbs) confer protection in nonhuman primates as late as 5 days after challenge, and FDA-approved mAbs REGN-EB3 and mAb114 have demonstrated efficacy against Ebola virus (EBOV) infection in humans. " 08/01/2021 - "Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus."
2.	Ebola Hemorrhagic Fever 01/01/2021 - "Based on the results of the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo, REGN-EB3 was recently approved by the US FDA as a treatment for Ebola virus infection. " 01/01/2022 - "These findings suggest that health-care workers should prioritise the use of REGN-EB3 and mAb114 for patients with Ebola virus disease during future outbreaks. " 02/07/2024 - "In this retrospective cohort analysis of patients with confirmed Ebola virus disease admitted to Ebola health facilities in the Democratic Republic of the Congo between July 27, 2018, and April 27, 2020, we performed univariate and multivariate analyses to assess case fatality risk and cycle threshold for nucleoprotein according to vaccination status, Ebola virus disease-specific treatments (eg, mAb114 and REGN-EB3), and other risk factors. " 08/01/2021 - "Atoltivimab/ maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved treatment for Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who is reverse transcription polymerase chain reaction (RT-PCR)-positive for Zaire ebolavirus infection. " 03/01/2024 - "Antibody concentrations were measured by the multiplex immunoassay, and the association between anti-Ebola virus antibody levels and the relevant exposures, such as anti-Ebola virus disease drugs (ansuvimab, REGN-EB3, ZMapp, or remdesivir), was assessed using both linear and logistic mixed regression models. "

Related Drugs and Biologics

1.	ansuvimab
2.	Monoclonal Antibodies
3.	atoltivimab, maftivimab, and odesivimab-ebgn drug combination
4.	remdesivir
5.	ZMapp
6.	Nucleoproteins